10 completed, 2 unknown, 1 active not recruiting. 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 10, Unknown 2, Active not recruiting 1 |
Follow ORA, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED) AZR-MD-001, Vehicle - Dry Eye Disease | Phase 3 | Unknown | Azura Ophthalmics | 500 | 2024-05-28 | 2024-09-27 |
| Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED) ST-100 (vezocolmitide), Vehicle - Dry Eye Disease | Phase 3 | Unknown | ORA, Inc. | 175 | 2023-12-29 | 2024-01-18 |
| A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye SI-614, Placebo - Dry Eye Disease | Phase 3 | Completed | Seikagaku Corporation | 232 | 2022-07-28 | 2026-01-16 |
| Study of OT-101 in Treating Myopia OT-101 Ophthalmic Solution, Vehicle - Myopia, Progressive | Phase 3 | Active not recruiting | Ocumension (Hong Kong) Limited | 678 | 2021-04-01 | 2023-08-08 |
| Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution - Dry Eye Syndrome | Phase 3 | Completed | Mitotech, SA | 610 | 2019-12-20 | 2022-01-19 |
| Study of SkQ1 as Treatment for Dry-eye Syndrome Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle) - Dry Eye Syndrome | Phase 3 | Completed | Mitotech, SA | 452 | 2018-12-06 | 2022-01-19 |
| A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model. Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Faes Farma, S.A. | 228 | 2018-04-07 | 2023-03-16 |
| A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle EM-100, Zaditor®, Vehicle - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 65 | 2018-04-07 | 2023-06-08 |
| A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution AC-170 0.24%, AC-170 Vehicle - Healthy Subjects | Phase 3 | Completed | Nicox Ophthalmics, Inc. | 516 | 2016-04-01 | 2017-09-11 |
| OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Dexamethasone, Placebo Vehicle - Chronic Allergic Conjunctivitis | Phase 3 | Completed | Ocular Therapeutix, Inc. | 86 | 2015-06-01 | 2020-10-12 |
| OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Dexamethasone, Placebo Vehicle - Chronic Allergic Conjunctivitis | Phase 3 | Completed | Ocular Therapeutix, Inc. | 73 | 2015-04-01 | 2018-03-29 |
| Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants Brimonidine Tartrate, Vehicle, Sodium Fluorescein - Hyperemia | Phase 3 | Completed | Bausch & Lomb Incorporated | 507 | 2014-02-22 | 2019-10-23 |
| Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness Brimonidine Tartrate, Vehicle, Sodium Fluorescein - Hyperemia | Phase 3 | Completed | Bausch & Lomb Incorporated | 60 | 2013-11-07 | 2019-10-23 |
Dry Eye Syndromes (5) · Conjunctivitis, Allergic (2) · Hyperemia (2) · Keratoconjunctivitis (2) · Myopia, Degenerative (1)
Brimonidine Tartrate (2) · Dexamethasone (2) · Fluorescein (2) · Visomitin (2) · Cetirizine (1) · Ketotifen (1) · ketotifen fumarate ophthalmic solution (1)
United States (11)
Heleen DeCory (2) · Lawrence T Friedhoff, MD, PhD (2) · Charles Bosworth, PhD (1) · Eugene Protzko, MD (1) · Gail Torkildsen, MD (1) · George Ousler (1) · Keith Lane (1) · M. Ali Haider, DO (1) · Ranjan Malhotra, MD (1) · Robert Rice, MD (1) · Stacey Ackerman, MD (1)
PMID 22435675, PMID 25686388, PMID 26689380, PMID 26890669, PMID 28956287, PMID 29461408, PMID 30248890, PMID 33882269, PMID 36811846, PMID 37260844